Novo Nordisk's first-generation weight loss drug Saxenda will have limited availability through the end of 2023 because of surging demand.

A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

Saxenda is used for weight management in certain people. Find out about cost, coupons, financial and insurance assistance, and more.

Novo Nordisk announced that the FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management.